Nnz-2566 (DrugBank: -)
2 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 156 | Rett syndrome | 2 |
| 206 | Fragile X syndrome | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02715115 (ClinicalTrials.gov) | March 2016 | 21/2/2016 | A Safety Study of NNZ-2566 in Pediatric Rett Syndrome | A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome | Rett Syndrome | Drug: NNZ-2566;Drug: Placebo | Neuren Pharmaceuticals Limited | rettsyndrome.org | Completed | 5 Years | 15 Years | Female | 82 | Phase 2 | United States |
| 2 | NCT01703533 (ClinicalTrials.gov) | March 2013 | 4/10/2012 | A Safety Study of NNZ-2566 in Patients With Rett Syndrome | A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome | Rett Syndrome | Drug: NNZ-2566;Drug: Placebo | Neuren Pharmaceuticals Limited | Baylor College of Medicine;International Rett Syndrome Foundation | Completed | 16 Years | 45 Years | Female | 67 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01894958 (ClinicalTrials.gov) | January 2014 | 3/7/2013 | A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome | A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome | Fragile X Syndrome | Drug: NNZ-2566;Drug: Placebo | Neuren Pharmaceuticals Limited | NULL | Completed | 12 Years | 45 Years | Male | 72 | Phase 2 | United States |